NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer by Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik, Peter C. Lucas, Ashok Srinivasan, Ying Wang, Nan Song, Patrick G. Gavin, April D. Balousek, Soonmyung Paik, Carmen J. Allegra, Norman Wolmark, Katherine L. Pogue-Geile

Subjects: Get full text

Trans-(−)-Kusunokinin: A Potential Anticancer Lignan Compound against HER2 in Breast Cancer Cell Lines? by Thidarath Rattanaburee, Tanotnon Tanawattanasuntorn, Tienthong Thongpanchang, Varomyalin Tipmanee, Potchanapond Graidist

Subjects: Get full text

Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers by Dakroub R, Huard S, Hajj-Younes Y, Suresh S, Badran B, Fayyad-Kazan H, Dubois T

Subjects: Get full text

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib by Sara Alkhezayem, Tanveer A. Wani, Salma Wakil, Ashwaq Aljuraysi, Seema Zargar

Subjects: Get full text

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib by Laurence Booth, Jane L. Roberts, Andrew Poklepovic, Paul Dent

Subjects: “…neratinib…”
Get full text

Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient’s response to conventional and novel therapies by Liting Liu, Min Wu, Anni Huang, Chun Gao, Yifan Yang, Hong Liu, Han Jiang, Long Yu, Yafei Huang, Hui Wang

Subjects: Get full text

UPLC-MS/MS Method for Simultaneous Estimation of Neratinib and Naringenin in Rat Plasma: Greenness Assessment and Application to Therapeutic Drug Monitoring by Ali Altharawi, Safar M. Alqahtani, Sagar Suman Panda, Majed Alrobaian, Alhumaidi B. Alabbas, Waleed Hassan Almalki, Manal A. Alossaimi, Md. Abul Barkat, Rehan Abdur Rub, Shehla Nasar Mir Najib Ullah, Mahfoozur Rahman, Sarwar Beg

Subjects: Get full text

The Conundrum of Adjuvant HER2 Treatment Options by Ajaz Bulbul, Ajaz Bulbul, Emilio Araujo-Mino, Emilio Araujo-Mino, Zoneddy Ruiz Dayao

Subjects: Get full text

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer by Ricardo Ribas, Sunil Pancholi, Aradhana Rani, Eugene Schuster, Stephanie K. Guest, Joanna Nikitorowicz-Buniak, Nikiana Simigdala, Allan Thornhill, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Mitch Dowsett, Stephen R. Johnston, Lesley-Ann Martin

Subjects: Get full text

Case Report: Neratinib Therapy Improves Glycemic Control in a Patient With Type 2 Diabetes and Breast Cancer by Vasileios Angelis, Stephen R. D. Johnston, Amin Ardestani, Amin Ardestani, Kathrin Maedler

Subjects: Get full text

Neratinib safety evaluation: real-world adverse event analysis from the FAERS database by Yunhe Fan, Teng Wu, Pengyang Xu, Chuanli Yang, Chuanli Yang, Chuanli Yang, Jie An, Haijia Zhang, Mureed Abbas, Xiushan Dong

Subjects: “…neratinib…”
Get full text

Neratinib for HER2-positive breast cancer with an overlooked option by Liting Guo, Weiwei Shao, Chenfei Zhou, Hui Yang, Liu Yang, Qu Cai, Junqing Wang, Yan Shi, Lei Huang, Jun Zhang

Subjects: “…Neratinib…”
Get full text

Study of Interactions of an Anticancer Drug Neratinib With Bovine Serum Albumin: Spectroscopic and Molecular Docking Approach by Tanveer A. Wani, Ahmed H. Bakheit, Ahmed H. Bakheit, M. A. Abounassif, Seema Zargar

Subjects: Get full text

DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer by Majid Momeny, Mari Tienhaara, Mukund Sharma, Deepankar Chakroborty, Roosa Varjus, Iina Takala, Joni Merisaari, Artur Padzik, Andreas Vogt, Ilkka Paatero, Klaus Elenius, Teemu D Laajala, Kari J Kurppa, Jukka Westermarck

Subjects: Get full text

Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats by Kate R. Secombe, Imogen A. Ball, Anthony D. Wignall, Emma Bateman, Dorothy M. Keefe, Joanne M. Bowen

Subjects: Get full text

Effects of neratinib on angiogenesis and the early stage of the embryo using chicken embryo as a model by Hadeel Kheraldine, Arij Fouzat Hassan, Hashim Alhussain, Hamda Al-Thawadi, Semir Vranic, Ala-Eddin Al Moustafa

Subjects: “…Neratinib…”
Get full text

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer by Nadia Harbeck

Subjects: Get full text

Analysis of Gut Microbiome Using Explainable Machine Learning Predicts Risk of Diarrhea Associated With Tyrosine Kinase Inhibitor Neratinib: A Pilot Study by Chi Wah Wong, Susan E. Yost, Jin Sun Lee, John D. Gillece, Megan Folkerts, Lauren Reining, Sarah K. Highlander, Zahra Eftekhari, Joanne Mortimer, Yuan Yuan

Subjects: Get full text

Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib‐induced diarrhea in HER2‐positive breast cancer—A pilot study by Joanne Bowen, Sofia Braga, Valeria Dal Zotto, John Finnie, Daniel DiPrimeo, Blaire Cooke, Georg F. Bischof, Alvin Wong, Jack A. Di Palma

Subjects: Get full text

Exceptional disease control with neratinib monotherapy in HER2-positive advanced breast cancer: A case report by Pierluigi di Mauro, Serena Capici, Viola Cogliati, Francesca Fulvia Pepe, Claudia Maggioni, Francesca Riva, Federica Cicchiello, Marina Elena Cazzaniga

Subjects: Get full text